Transthyretin amyloidosis with cardiomyopathy (ATTR-CM) is a fatal disease. Methods are needed to monitor patients with disease progression and optimize treatment decisions. Outpatient worsening heart failure (HF) (oral diuretic intensification or initiation) has been shown to be prognostic of mortality in patients with ATTR-CM. In the HELIOS-B trial, vutrisiran reduced the risk of all-cause mortality (ACM) and recurrent CV events vs placebo in patients with ATTR-CM.

To investigate the clinical and prognostic value of–in addition to the effect of vutrisiran on–outpatient worsening HF in patients with ATTR-CM.

Associations between outpatient worsening HF and the HELIOS-B primary composite of ACM and recurrent CV events, ACM alone, and other disease progression-related endpoints were evaluated. The impact of vutrisiran over 36M on outpatient worsening HF and an expanded composite of ACM, recurrent CV events, and outpatient worsening HF was also assessed.

In the overall population (n=655 randomized), 321 (49.1%) patients had≥1 outpatient worsening HF event, 245 (37.5%) had≥1 CV event(s), and 120 (18.3%) died; 237 patients (36.2%) had no events. Patients with, vs those without, outpatient worsening HF had an increased risk of ACM and CV events (hazard ratio [HR] 2.58, 95% confidence interval [CI] 2.04, 3.27) and ACM (HR 2.45, 95% CI 1.70, 3.52) (Figure 1), as well as greater deterioration in 6-MWT and KCCQ-OS, and a greater increase in NT-proBNP. In recurrent event analyses over the double-blind period, vutrisiran reduced the rate of outpatient worsening HF (relative rate ratio 0.66, 95% CI 0.56, 0.78) vs placebo. Vutrisiran also reduced the risk of the composite of ACM, recurrent CV events and outpatient worsening HF vs placebo (HR 0.69 [95% CI 0.57, 0.83]) (Figure 1, Figure 2).

Outpatient worsening HF was frequent in patients with ATTR-CM and was associated with an increased risk of mortality and recurrent CV events. Vutrisiran reduced the risk of outpatient worsening HF vs placebo.